Drug Trial Radar · NCT06062069
A Study of CT-868 in Type 1 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Nov 27, 2023
Primary completion
Jul 7, 2025
Study completion Jul 7, 2025
Sponsor
- Lead sponsor
- Carmot Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Conditions
- Overweight
- Obese
- Type 1 Diabetes Mellitus
Interventions
CT-868Drug
CT-868 is an investigational medication administered subcutaneously via a pre-filled pen injector device.
CT-868 Pen InjectorDevice
The CT-868 pen injector is a multi-dose, single-participant, disposable pen.
CT-868 Pen Injector, PlaceboDrug
The placebo pen injector is identical and contains the same ingredients except for CT-868.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Glycated Hemoglobin (HbA1c) (%) at Week 16Time frame: Baseline (Day 1) to Week 16
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
John Muir Physician Network Clinical Research Center
Concord, California
Headlands Research- AMCR
Escondido, California
University of Colorado - Barbara Davis Center for Diabetes
Aurora, Colorado
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
Advent Health
Orlando, Florida
Orlando Health Science Clinic, LLC
Orlando, Florida
Innovative Research Institute
Port Charlotte, Florida
Atlanta Diabetes Associates
Atlanta, Georgia
Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho
Idaho Falls, Idaho
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
MedStar Health Research Institute - Washington Hospital Center
Hyattsville, Maryland
University of North Carolina Health Sciences at MAHEC
Asheville, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Lucas Research, Inc
Morehead City, North Carolina
Oregon Health and Science University
Portland, Oregon
Texas Diabetes and Endocrinology, P.A
Austin, Texas
Velocity Clinical Research - Dallas
Dallas, Texas
Research Institute of Dallas
Dallas, Texas
Diabetes & Glandular Disease Clinic, P.A.
San Antonio, Texas
Consano Clinical Research
Shavano Park, Texas
Texas Valley Clinical Research, LLC
Weslaco, Texas
Rainier Clinical Research Center
Renton, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.